Progression of cerebral amyloid load is associated with the apolipoprotein e ε4 genotype in Alzheimer's disease

Biological Psychiatry

Volumn 68, Issue 10, 2010, Pages 879-884

  Grimmer, Timo ^a   Tholen, Susanne ^a   Yousefi, Behrooz H ^a   Alexopoulos, Panagiotis ^a   Frschler, Annette ^a   Frstl, Hans ^a   Henriksen, Gjermund ^a   Klunk, William E ^b   Mathis, Chester A ^c   Perneczky, Robert ^a   Sorg, Christian ^a   Kurz, Alexander ^a   Drzezga, Alexander ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; apolipoprotein E; Pittsburgh Compound B; positron emission tomography; prospective study

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E EPSILON 4; APOLIPOPROTEIN E4; BRAIN PROTEIN; CARBON 11; FLUORODEOXYGLUCOSE F 18; MARKER; PITTSBURGH COMPOUND B; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG UPTAKE; FEMALE; GENE DOSAGE; GENOTYPE; HUMAN; IMAGE ANALYSIS; MALE; MINI MENTAL STATE EXAMINATION; NEOCORTEX; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYMPTOM;

AGED; ALZHEIMER DISEASE; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; BRAIN; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 78049427912     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.05.013     Document Type: Article

References (38)

1. H. Braak, and E. Braak Neuropathological staging of Alzheimer-related changes Acta Neuropathol 82 1991 239 259
2. D.R. Thal, U. Rb, M. Orantes, and H. Braak Phases of Aβ-deposition in the human brain and its relevance for the development of AD Neurology 58 2002 1791 1800
3. S. Cosentino, N. Scarmeas, E. Helzner, M.M. Glymour, J. Brandt, and M. Albert APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease Neurology 70 2008 1842 1849
4. S. Craft, L. Teri, S.D. Edland, W.A. Kukull, G. Schellenberg, and W.C. McCormick Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease Neurology 51 1998 149 153
5. E. Mori, K. Lee, M. Yasuda, M. Hashimoto, H. Kazui, N. Hirono, and M. Matsui Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele Ann Neurol 51 2002 209 214
6. M. Lehtovirta, J. Kuikka, S. Helisalmi, P. Hartikainen, A. Mannermaa, and M. Ryynanen Longitudinal SPECT study in Alzheimer's disease: Relation to apolipoprotein E polymorphism J Neurol Neurosurg Psychiatry 64 1998 742 746
7. A. Drzezga, M. Riemenschneider, B. Strassner, T. Grimmer, M. Peller, and A. Knoll Cerebral glucose metabolism in patients with AD and different APOE genotypes Neurology 64 2005 102 107
8. A. Drzezga, T. Grimmer, G. Henriksen, M. Muhlau, R. Perneczky, and I. Miederer Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease Neurology 72 2009 1487 1494
9. M.D. Ikonomovic, W.E. Klunk, E.E. Abrahamson, C.A. Mathis, J.C. Price, and N.D. Tsopelas Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 2008 1630 1645
10. A. Lockhart, J.R. Lamb, T. Osredkar, L.I. Sue, J.N. Joyce, and L. Ye PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis Brain 130 2007 2607 2615
11. M.T. Fodero-Tavoletti, D.P. Smith, C.A. McLean, P.A. Adlard, K.J. Barnham, and L.E. Forster In vitro characterization of Pittsburgh compound-B binding to Lewy bodies J Neurosci 27 2007 10365 10371
12. L. Ye, A. Velasco, G. Fraser, T.G. Beach, L. Sue, and T. Osredkar In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain J Neurochem 105 2008 1428 1437
13. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Ann Neurol 55 2004 306 319
14. H. Engler, A. Forsberg, O. Almkvist, G. Blomquist, E. Larsson, and I. Savitcheva Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain 129 2006 2856 2866
15. N.M. Scheinin, S. Aalto, J. Koikkalainen, J. Lotjonen, M. Karrasch, and N. Kemppainen Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls Neurology 73 2009 1186 1192
16. C.R. Jack Jr, V.J. Lowe, S.D. Weigand, H.J. Wiste, M.L. Senjem, and D.S. Knopman Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease Brain 132 2009 1355 1365
17. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini Mental State." A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
18. M. Berres, A.U. Monsch, F. Bernasconi, B. Thalmann, and H.B. Stahelin Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease Stud Health Technol Inform 77 2000 195 199
19. J.C. Morris, A. Heyman, R.C. Mohs, J.P. Hughes, G. van Belle, and G. Fillenbaum The Consortium to Establish a Registry for Alzheimer's disease (CERAD) Part I. Clinical and neuropsychological assessment of Alzheimer's disease Neurology 39 1989 1159 1165
20. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
21. J.M. Hoffman, K.A. Welsh-Bohmer, M. Hanson, B. Crain, C. Hulette, N. Earl, and R.E. Coleman FDG PET imaging in patients with pathologically verified dementia J Nucl Med 41 2000 1920 1928
22. W. Jagust, B. Reed, D. Mungas, W. Ellis, and C. Decarli What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69 2007 871 877
23. S. Minoshima Imaging Alzheimer's disease: Clinical applications Neuroimaging Clin N Am 13 2003 769 780
24. G.C. Roman, T.K. Tatemichi, T. Erkinjuntti, J.L. Cummings, J.C. Masdeu, and J.H. Garcia Vascular dementia: Diagnostic criteria for research studies Report of the NINDS-AIREN International workshop Neurology 43 1993 250 260
25. A. Zivelin, N. Rosenberg, H. Peretz, Y. Amit, N. Kornbrot, and U. Seligsohn Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes Clin Chem 43 1997 1657 1659
26. T. Grimmer, G. Henriksen, H.J. Wester, H. Forstl, W.E. Klunk, and C.A. Mathis Clinical severity of Alzheimer's disease is associated with PIB uptake in PET Neurobiol Aging 30 2009 1902 1909
27. T. Grimmer, M. Riemenschneider, H. Forstl, G. Henriksen, W.E. Klunk, and C.A. Mathis Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid Biol Psychiatry 65 2009 927 934
28. N. Tzourio-Mazoyer, B. Landeau, D. Papathanassiou, F. Crivello, O. Etard, and N. Delcroix Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain Neuroimage 15 2002 273 289
29. A.M. Loening, and S.S. Gambhir AMIDE: A free software tool for multimodality medical image analysis Mol Imaging 2 2003 131 137
30. M.J. Chandler, L.H. Lachritz, H.D. Bernard, G. Allen, M. Deschner, and M.F. Weiner A total score for the CERAD neuropsychological battery Neurology 65 2005 102 106
31. K.J. Friston, A.P. Holmes, and K.J. Worsley Statistical parametric mapping in functional imaging: A general linear approach Hum Brain Mapp 2 1995 189 210
32. S. Aalto, N.M. Scheinin, N.M. Kemppainen, K. Nagren, M. Kailajarvi, and M. Leinonen Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data Eur J Nucl Med Mol Imaging 36 2009 1651 1660
33. N. Tolboom, M. Yaqub, R. Boellaard, G. Luurtsema, A.D. Windhorst, and P. Scheltens Testretest variability of quantitative [11C]PIB studies in Alzheimer's disease Eur J Nucl Med Mol Imaging 36 2009 1629 1638
34. R. Cabeza, and L. Nyberg Imaging cognition II: An empirical review of 275 PET and fMRI studies J Cogn Neurosci 12 2000 1 47
35. M. Moscovitch, R.S. Rosenbaum, A. Gilboa, D.R. Addis, R. Westmacott, and C. Grady Functional neuroanatomy of remote episodic, semantic and spatial memory: A unified account based on multiple trace theory J Anat 207 2005 35 66
36. R.G. Schlosser, G. Wagner, and H. Sauer Assessing the working memory network: Studies with functional magnetic resonance imaging and structural equation modeling Neuroscience 139 2006 91 103
37. G. Gold, E. Kvari, G. Corte, F. Herrmann, A. Canuto, and T. Bussiere Clinical validity of Aβ-protein deposition staging in brain aging and Alzheimer disease J Neuropathol Exp Neurol 60 2001 946 952
38. D.W. McKeel, J.L. Price, J.P. Miller, E.A. Grant, C. Xiong, L. Berg, and J.C. Morris Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type J Neuropathol Exp Neurol 63 2004 1028 1037